Zhao-Song DU1, Hua Xu1, Mao-Chang Liu1. 1. Department of Pharmacy, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Scienc & Technology, Wuhan 430016, China.
Abstract
OBJECTIVE: To study the medication in children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Wuhan, China, and to provide a reference for rational drug use in clinical practice. METHODS: A retrospective analysis was performed on the medical data of the children who were diagnosed with SARS-CoV-2 infection from January 26 to March 5, 2020. The children were divided into an asymptomatic group with 41 children and a symptomatic group with 73 children. A subgroup analysis was performed to investigate the effect of different antiviral regimens (monotherapy, double therapy, or triple therapy) and whether interferon α-1b was used in combination with azithromycin on the length of hospital stay and the clearance time of SARS-CoV-2 nucleic acid. RESULTS: A total of 114 children with SARS-CoV-2 infection (72 boys and 42 girls) were enrolled. The median age of the children was 7.1 years. The median length of hospital stay was 10 days and the clearance time of SARS-CoV-2 nucleic acid was 6 days. In either group, the subgroup analysis showed no significance differences in the length of hospital stay and the clearance time of SARS-CoV-2 nucleic acid between the subgroups treated with different combinations of antiviral drugs and the subgroups treated with interferon α-1b alone or in combination with azithromycin (P > 0.05). CONCLUSIONS: It is not recommended to use the routine combinations of antiviral drugs for children with SARS-COV-2 infection or combine with azithromycin for the purpose of antiviral therapy.
OBJECTIVE: To study the medication in children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Wuhan, China, and to provide a reference for rational drug use in clinical practice. METHODS: A retrospective analysis was performed on the medical data of the children who were diagnosed with SARS-CoV-2 infection from January 26 to March 5, 2020. The children were divided into an asymptomatic group with 41 children and a symptomatic group with 73 children. A subgroup analysis was performed to investigate the effect of different antiviral regimens (monotherapy, double therapy, or triple therapy) and whether interferon α-1b was used in combination with azithromycin on the length of hospital stay and the clearance time of SARS-CoV-2 nucleic acid. RESULTS: A total of 114 children with SARS-CoV-2 infection (72 boys and 42 girls) were enrolled. The median age of the children was 7.1 years. The median length of hospital stay was 10 days and the clearance time of SARS-CoV-2 nucleic acid was 6 days. In either group, the subgroup analysis showed no significance differences in the length of hospital stay and the clearance time of SARS-CoV-2 nucleic acid between the subgroups treated with different combinations of antiviral drugs and the subgroups treated with interferon α-1b alone or in combination with azithromycin (P > 0.05). CONCLUSIONS: It is not recommended to use the routine combinations of antiviral drugs for children with SARS-COV-2 infection or combine with azithromycin for the purpose of antiviral therapy.
Authors: Hanna Retallack; Elizabeth Di Lullo; Carolina Arias; Kristeene A Knopp; Matthew T Laurie; Carmen Sandoval-Espinosa; Walter R Mancia Leon; Robert Krencik; Erik M Ullian; Julien Spatazza; Alex A Pollen; Caleigh Mandel-Brehm; Tomasz J Nowakowski; Arnold R Kriegstein; Joseph L DeRisi Journal: Proc Natl Acad Sci U S A Date: 2016-11-29 Impact factor: 11.205
Authors: Jonathan Grein; Norio Ohmagari; Daniel Shin; George Diaz; Erika Asperges; Antonella Castagna; Torsten Feldt; Gary Green; Margaret L Green; François-Xavier Lescure; Emanuele Nicastri; Rentaro Oda; Kikuo Yo; Eugenia Quiros-Roldan; Alex Studemeister; John Redinski; Seema Ahmed; Jorge Bernett; Daniel Chelliah; Danny Chen; Shingo Chihara; Stuart H Cohen; Jennifer Cunningham; Antonella D'Arminio Monforte; Saad Ismail; Hideaki Kato; Giuseppe Lapadula; Erwan L'Her; Toshitaka Maeno; Sumit Majumder; Marco Massari; Marta Mora-Rillo; Yoshikazu Mutoh; Duc Nguyen; Ewa Verweij; Alexander Zoufaly; Anu O Osinusi; Adam DeZure; Yang Zhao; Lijie Zhong; Anand Chokkalingam; Emon Elboudwarej; Laura Telep; Leighann Timbs; Ilana Henne; Scott Sellers; Huyen Cao; Susanna K Tan; Lucinda Winterbourne; Polly Desai; Robertino Mera; Anuj Gaggar; Robert P Myers; Diana M Brainard; Richard Childs; Timothy Flanigan Journal: N Engl J Med Date: 2020-04-10 Impact factor: 91.245
Authors: Philippe Gautret; Jean-Christophe Lagier; Philippe Parola; Van Thuan Hoang; Line Meddeb; Morgane Mailhe; Barbara Doudier; Johan Courjon; Valérie Giordanengo; Vera Esteves Vieira; Hervé Tissot Dupont; Stéphane Honoré; Philippe Colson; Eric Chabrière; Bernard La Scola; Jean-Marc Rolain; Philippe Brouqui; Didier Raoult Journal: Int J Antimicrob Agents Date: 2020-03-20 Impact factor: 5.283
Authors: J M Molina; C Delaugerre; J Le Goff; B Mela-Lima; D Ponscarme; L Goldwirt; N de Castro Journal: Med Mal Infect Date: 2020-03-30 Impact factor: 2.152
Authors: Rudolf Lucas; Yalda Hadizamani; Perenlei Enkhbaatar; Gabor Csanyi; Robert W Caldwell; Harald Hundsberger; Supriya Sridhar; Alice Ann Lever; Martina Hudel; Dipankar Ash; Masuko Ushio-Fukai; Tohru Fukai; Trinad Chakraborty; Alexander Verin; Douglas C Eaton; Maritza Romero; Jürg Hamacher Journal: Front Physiol Date: 2022-02-21 Impact factor: 4.755